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Education and debate
Paying for statins
Nick Raithatha, Richard D Smith
Should UK general practitioners be able to offer private prescriptions for statins to patients below
3% risk of heart disease?
Coronary heart disease is a major cause of illness in
Britain, with around 100 000 deaths from 300 000
heart attacks annually.1 2 Raised cholesterol concentra-
tion is an important risk factor for coronary heart dis-
ease.3 Treatment with 3-hydroxy-3-methylglutaryl
coenzyme reductase inhibitors (statins) significantly
reduces cholesterol concentrations, decreasing the risk
of heart attack by at least 33%4 and as much as 61% in
the long term.5 Statins are relatively safe,6 and their
benefit is additive to other preventive measures, such as
aspirin.7 However, many people who could benefit
from them are not currently receiving them, largely for
economic reasons. This article explains the rationale
for increasing prescribing of statins and suggests one
way in which this could be afforded.
Cost of treatment
Current evidence shows that statins reduce the risk of
developing coronary heart disease in people with a
greater than 0.6% a year chance of developing the
disease.8 However, the national service framework that
establishes standards for the prevention of coronary
heart disease recommends treatment only for people
with a risk of over 3% a year.1 The cost effectiveness of
statins (based on a benefit of 33%) has been estimated at
£4500 ($8250, €6460) per life year gained for a year’s
treatment of people at a 3% annual risk of coronary
heart disease and £6100 a year for people at a 1.5%
annual risk; the net discounted cost per life year saved to
the NHS is £7500 and £11 800 respectively.9 The
marginal cost to the NHS of expanding treatment from
those at 3% risk to those at 1.5% risk would be £12 500
per life year saved.9 This is well within the threshold of
£30 000 per life year gained that the National Institute
for Clinical Excellence seems to use.10
But this is not necessarily the good news that it
sounds. Cost effectiveness analysis does not take
account of total budgetary impact; prescribing statins
for those whose annual risk is over 3% would lead to
treating 8.2% of the adult British population, whereas
treatment for those whose risk is greater than 0.6%
would lead to treatment of over 40% of the adult
population.11 The annual cost of statins to the NHS,
based on a daily dose of 40 mg of simvastatin, is £337
for each patient.12 Forty per cent of the adult British
population is around 18 million.13 Thus, if all eligible
adults were treated, the total drug cost would be over
£6bn—about 10% of the total NHS budget.
Simvastatin has now lost its patent, and its price is
likely to fall. However, if we take the recent example of
fluoxetine, generic competition reduced the price only
to £66 a year.12 Even at this price, treating all eligible
patients would still cost over £1bn.
Ethical problem
All of this raises ethical issues for general practitioners.
They can treat all patients with raised blood pressure
and give advice about smoking, exercise, and diet, but
they can prescribe statins only to those with a risk of
greater than 3% a year despite knowing that many
more would benefit.1 Clearly, if all general practitioners
prescribed statins based on effectiveness, or even cost
effectiveness, they could bankrupt the NHS.
The problem is compounded by the ban on
general practitioners giving private prescription to
their NHS patients. Private prescriptions break the
core NHS principle to “provide a universal service for
all based on clinical need, not ability to pay.”14 However,
although private prescription would increase inequal-
ity in access to health care, is this necessarily unethical?
We suggest not. Rather, we believe it is both economi-
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cally and ethically justifiable to allow general
practitioners to prescribe statins privately, not only
because of the benefit to the person taking statins but
because of the broader positive effects that will accrue
to the rest of society.
The key issue is that patients who are currently
ineligible for statins are invariably not informed of this
form of rationing and as such are not able to choose
other, private, means of obtaining treatment. However,
many patients, if told that they could benefit from stat-
ins might be willing to pay for a private prescription.
This will depend on the individual’s valuation of (the
benefit derived from) statins relative to other potential
subjects of expenditure and income.15
We have estimated that the cost of private
treatment with monitoring by a NHS practice nurse
working within a protocol, is £93.66 a year (table).16
This is far less than median household expenditure on,
for example, alcohol (£320), clothes (£380), and
motoring (£920).13 Statins may therefore be quite
affordable to people on average earnings.
Ethics of private prescriptions
Under our proposed scenario, people with a choles-
terol concentration corresponding to a risk of
coronary heart disease of between 0.6% and 3% a year
would be offered private treatment and monitoring by
their own primary care team. This would ensure a
patient specific holistic approach to managing risk. In
addition to the benefits to the individual, the total inci-
dence of coronary heart disease would fall because
more people would be treated with statins. This would,
at the very least, make no one worse off, but it may save
NHS expenditure on treating coronary heart disease,
releasing money to spend elsewhere. In this case, it
would be possible for the NHS, through primary care
trusts, to target such savings to poorer areas—for
example, for primary prevention of coronary heart
disease. Allowing those who can afford private
prescriptions for statins to have them could therefore
also benefit those who cannot afford them.
Although increasing inequality, this is ethically jus-
tifiable under the difference principle.17 This is a form
of inequality whereby all members of society gain,
which has been argued to be ethically just by John
Rawls and others.17 Although relative inequality in
access would increase, absolute levels of health care
would increase, which would benefit all individuals in
society irrespective of their ability to pay. The pursuit of
equity under the current situation simply ensures that
everyone is equally worse off than they could be under
our proposed scenario.
Conclusions
The debate concerning access to statins is a parable for
the future of the NHS. Under current guidelines many
people are being denied not only effective treatment
but also the choice of obtaining that treatment though
their own expense within the NHS (in itself
paradoxical given the current emphasis of government
on promoting patient choice).18 The government has
proposed making statins available over the counter, but
there is considerable resistance to this because
treatment would be unmonitored. The current option
of treatment through a private consultant would be
prohibitively expensive for many. We suggest that
unless patients who are excluded from effective
treatment (because of rationing) are offered the option
of obtaining this treatment privately, it is this inequity
that will threaten the future of the NHS.
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†Generic price based on example of fluoxetine.
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Patient commentary: paying to choose
Everyone likes the idea of choice. The world would be
a boring place without it. When that choice extends to
extending your chances of living a long and happy life
rather than dying or being debilitated by coronary
heart disease, it becomes even more appealing. If I ever
had high cholesterol concentrations I would desper-
ately attempt to alter my lifestyle, probably fail
miserably, and end up back at the general practitioner
with my cheque book in hand begging for the wonder
drug that would keep my cholesterol concentration
under control.
Intellectually, I feel guilty about inequality and
inability to pay. I think it is a fundamental “right” that
everyone should get drugs that save lives or avoid
unnecessary suffering. However, as Raithatha and
Smith point out, there is a limit on who gets support,
and NHS finances don’t stretch as far as they should.
So should everyone suffer as a result? I think not.
Just in case my guilt does not disappear, the
authors come out with soothing statistics about the
costs of private treatment compared with household
expenditure on alcohol, clothes, and motoring
showing statins could be affordable. Then there is the
argument that, if people go private, the total incidence
of coronary heart disease would fall so that NHS
money would be released for the general good. I think
my guilt has disappeared—almost.
I am perhaps more worried about the practical
implications of encouraging overworked and stressed
general practitioners to write out private prescriptions.
Patients react to illness in different ways. Some want to
question, to weigh up the alternatives, to perhaps seek
a second opinion. Others just want their general prac-
titioners to tell them what to do.
This could put general practitioners in an awkward
position. They might have to make an instant judgment
on whether a patient could afford a private prescription;
they might find themselves prescribing a drug that they
have not had time to research thoroughly; they might be
under pressure within their own budgets, and it would
be so easy to push the private option. Theymight also be
under pressure from the “unbeatable” sales pitch from
the drugs company. Under these circumstances could
patients really get an accurate picture of the risks or
benefits? I wonder.
To give a choice to the 32% of the adult population
currently denied effective treatment for high choles-
terol concentrations certainly sounds desirable, but
would they get an informed choice? Probably not.
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Ward rounds ain’t what they used to be
My first experience of ward rounds was as a first year clinical
student in 1950. The professorial parade occurred on two
afternoons a week, and, with the professor’s known wartime naval
career, there was a background of naval terminology, such as the
ward being unofficially known as the quarterdeck. The professor’s
retinue of assistants, lecturers, house surgeons, and many others
was so large that, by the time he had reached the second bed in
the clockwise circuit of the Nightingale ward, the last of us were
still coming in through the ward doors. After that the ward doors
were closed and guarded by a porter to deter any unauthorised
person who might inadvertently enter and disturb the churchlike
tranquillity that prevailed during the event. Every so often, word
would come down the line about what was happening or being
said among the great ones up at the front. There was an
atmosphere of important decision making.
Once in a while, a request would arrive at the back for the
medical student who had been allocated a particular patient to
come up to the front in order to participate in the muttered case
conference at the bedside that was taking place beyond earshot
for the rest of us. On arrival up at the front, the medical student
was awarded the title, for some archaic reason, of “Mr Dresser.”
The patients lay to attention in freshly made beds, and starched
nurses stood about, eager to assist those patients who might be
examined. As the professor moved on, a junior acolyte would be
deputed to whisper to the patient what the professor had said.
But there were occasional lighter moments. The professor was
a kindly man of dignified stature, and on one day there happened
to be a scruffy young boy who had just been admitted with
abdominal pain. Wishing to demonstrate his charm and
paternalistic skills, the smiling professor gently poked him in the
stomach and said, “And how are we today, young man?”
To which the boy responded in a surprisingly loud voice, “Buzz
off, fatty.”
In the shocked silence that followed, there were many
semi-controlled smirks, and the professor actually blushed as he
left his first assistant to deal with the problem. It obviously ruined
his day, and I felt I had witnessed a latter day version of David and
Goliath. Also, it was an early valuable lesson that actors have
always understood: never try to score points off children.
In my latter days of clinical practice, my early morning rounds
were a great contrast—always noisy and chaotic, with patients
coming and going on rattling trolleys and wheelchairs,
telephones ringing, frantic searching for the results of
investigations or patients’ notes, and the instruction of new junior
doctors in their duties. Actually, I thought these rounds worked
well for good patient care, but I often wondered whether the
pendulum of formality had swung too far the other way.
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